Clinical Trial Detail

NCT ID NCT02588105
Title Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Olaparib

AZD0156

Age Groups: adult

No variant requirements are available.